US looking to procure ‘adapted’ vaccines — Analysis
Pending approval from regulators, the US government will buy jabs specially ‘adapted’ to the Covid-19 Omicron strain, Pfizer said
US health officials will purchase additional coronavirus vaccinations worth more than 3 billion dollars from Pfizer. Pfizer noted that the sales could also include an Omicron vaccine, currently under review by federal regulators.
Pfizer and BioNTech, the German partner of Pfizer, announced their latest vaccine deal Wednesday afternoon. It stated that they would deliver 105,000,000 doses in return for $3.2 billion. There are also options to purchase additional 195,000,000 shots, should the government choose.
“This agreement will provide additional doses for US residents and help cope with the next Covid-19 wave,”Sean Marett (CEO BioNTech) said that this was in addition to the fact that “Pending regulatory authorization, it will also include an Omicron-adapted vaccine, which we believe is important to address the rapidly spreading Omicron variant.”
Pfizer approves vaccine boosters for the younger age group
According to the firms, they supplied FDA with food and drug administration (FDA). “pivotal data”On the “safety” “tolerability”Last weekend saw the release of Omicron-adapted candidates for vaccines. “positive”Results from lab tests. They have begun manufacturing the doses of each candidate even before they receive approval. “at risk”In order to “begin deliveries rapidly upon authorization.”
UNICEF data shows that the vaccine developed by BioNTech and Pfizer is one of the most popular immunizations for the coronavirus. It has been approved in 111 countries, according to UNICEF. The vaccine has been a windfall for the pharma firms, becoming one of the most lucrative products in modern history and helping to double Pfizer’s yearly revenue between 2020 and 2021.
Share this story via social media